Evidence map›Paper›PMID 36038671›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2023

A patterns of care analysis of hyperthermia in combination with radio(chemo)therapy or chemotherapy in European clinical centers.

Adela Ademaj, Paraskevi D Veltsista, Dietmar Marder, Roger A Hälg, Emsad Puric, Thomas B Brunner, Hans Crezee, Dorota Gabrys, Martine Franckena, Cihan Gani and 14 more

Abstract read
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Survey in radiation oncology departments in Germany, Austria, and Switzerland: state of digitalization by 2023.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Adela AdemajCentre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, Switzerland.ORCID 0000-0001-6568-7198
Paraskevi D VeltsistaDepartment Radiation Oncology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Dietmar MarderCentre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, Switzerland.ORCID 0000-0003-0865-9283
Roger A HälgCentre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, Switzerland.
Emsad PuricCentre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, Switzerland.
Thomas B BrunnerDepartment of Radiation Oncology, University Hospital Magdeburg, Magdeburg, Germany.
Hans CrezeeDepartment of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-7474-0533
Dorota GabrysDepartment of Radiation Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch, Poland.ORCID 0000-0001-9096-2788
Martine FranckenaDepartment of Radiation Oncology, , Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Cihan GaniCentre for Radiation Oncology, University Hospital Tübingen, Tübingen, Germany.
Michael R HorsmanDepartment of Clinical Medicine and Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
Robert KrempienDepartment of Radiation Oncology, Helios Hospital Berlin-Buch, Berlin, Germany.
Lars H LindnerDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Sergio MalutaDepartment of Hyperthermia, Serena Medical Center, Padova, Italy.
Markus NotterDepartment of Radiation Oncology, Lindenhof Hospital, Bern, Switzerland.
Griseldis PetzoldDepartment of Radiation Oncology, Hospital Chemnitz, Chemnitz, Germany.
Sultan Abdel-RahmanDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Antonella RichettiRadiation Oncology Clinic, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Andreas R ThomsenDepartment of Radiation Oncology, University Hospital Freiburg, Freiburg, Germany.
Pelagia TsoutsouDepartment of Radiation Oncology, Geneva University Hospitals, Geneva, Switzerland.
Rainer FietkauDepartment of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
Oliver J OttDepartment of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.ORCID 0000-0001-5806-6158
Pirus GhadjarDepartment Radiation Oncology, Charité Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-2747-165X
Oliver RiestererCentre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, Switzerland. oliver.riesterer@ksa.ch.ORCID 0000-0002-9508-0546

Funding

HORIZON EUROPE Marie Sklodowska-Curie Actions 955625
6 · The paper itself

Abstract

purposeThe combination of hyperthermia (HT) with radio(chemo)therapy or chemotherapy (CT) is an established treatment strategy for specific indications. Its application in routine clinical practice in Europe depends on regulatory and local conditions. We conducted a survey among European clinical centers to determine current practice of HT.

methodsA questionnaire with 22 questions was sent to 24 European HT centers. The questions were divided into two main categories. The first category assessed how many patients are treated with HT in combination with radio(chemo)therapy or CT for specific indications per year. The second category addressed which hyperthermia parameters are recorded. Analysis was performed using descriptive methods.

resultsThe response rate was 71% (17/24) and 16 centers were included in this evaluation. Annually, these 16 centers treat approximately 637 patients using HT in combination with radio(chemo)therapy or CT. On average, 34% (range: 3-100%) of patients are treated in clinical study protocols. Temperature readings and the time interval between HT and radio(chemo)therapy or CT are recorded in 13 (81%) and 9 (56%) centers, respectively. The thermal dose quality parameter "cumulative equivalent minutes at 43 °C" (CEM43°C) is only evaluated in five (31%) centers for each HT session. With regard to treatment sequence, 8 (50%) centers administer HT before radio(chemo)therapy and the other 8 in the reverse order.

conclusionThere is a significant heterogeneity among European HT centers as to the indications treated and the recording of thermometric parameters. More evidence from clinical studies is necessary to achieve standardization of HT practice.

Indexed as

Hyperthermia, InducedCombined Modality TherapyEuropeHumansThermal doseThermometric parameterTime intervalTreatment sequenceTreatment standardization

Identifiers

PMID36038671
PMCPMC10133066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.